Pfizer Inc. $PFE Holdings Lifted by Quintet Private Bank Europe S.A.

Key Points

• Quintet Private Bank Europe increased its Pfizer stake by 40.6% in the third quarter, bringing its holdings to 684,746 shares worth approximately $19.5 million. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer shares recently traded at $27.74, down 0.9%, while the company reported quarterly EPS and revenue above analyst expectations. Analysts maintain a consensus “Hold” rating with an average price target of $28.61.
• Pfizer declared a quarterly dividend of $0.43, equivalent to a roughly 6.2% annual yield. However, the high payout ratio, elevated debt, restructuring activity and other cost pressures create questions about long-term dividend sustainability.

Quintet Private Bank Europe S.A. raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 40.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 684,746 shares of the biopharmaceutical company's stock after acquiring an additional 197,811 shares during the period. Pfizer makes up 0.9% of Quintet Private Bank Europe S.A.'s portfolio, making the stock its 26th biggest position. Quintet Private Bank Europe S.A.'s holdings in Pfizer were worth $19,529,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC increased its holdings in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in shares of Pfizer during the second quarter worth about $26,000. Field & Main Bank acquired a new position in shares of Pfizer during the second quarter worth about $27,000. Evolution Wealth Management Inc. boosted its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the period. Finally, Bullseye Investment Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.9%

Shares of Pfizer stock traded down $0.26 on Thursday, hitting $27.74. 11,910,174 shares of the company's stock traded hands, compared to its average volume of 40,384,527. The stock has a market cap of $158.09 billion, a P/E ratio of 36.51, a PEG ratio of 1.85 and a beta of 0.32. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $29.21. The firm's 50-day moving average is $27.56 and its 200 day moving average is $26.48.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date is Friday, November 6th. Pfizer's payout ratio is 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA regimen, in combination with trastuzumab and pertuzumab, as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. The expanded indication could increase TUKYSA’s addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Pfizer reported positive Phase 3 results for LITFULO in nonsegmental vitiligo, with meaningful facial and total-body repigmentation and favorable tolerability. Planned regulatory submissions could broaden the drug’s commercial opportunity and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results
• Neutral Sentiment: Cantor Fitzgerald raised its Pfizer price target from $27 to $28 but kept a neutral rating, implying limited upside at recent trading levels. Cantor Fitzgerald Raises Pfizer Price Target
• Neutral Sentiment: Pfizer declared its regular $0.43 quarterly dividend, equal to $1.72 annually and a yield of roughly 6%. The payout may attract income-focused investors, although the announcement itself does not change the company’s underlying earnings outlook. Pfizer Declares Fourth-Quarter 2026 Dividend
• Negative Sentiment: Analysts and financial commentary continue to flag risks behind Pfizer’s low valuation and high dividend yield, including a previously frozen payout, elevated debt, a multibillion-dollar write-down, and a reported payout ratio above earnings. These factors raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, facility, highlighting ongoing cost pressure and restructuring needs. Investors may view the reductions as evidence of continued operational challenges despite Pfizer’s cost-cutting program. Pfizer to Cut Around 330 Jobs in Italy

Analyst Ratings Changes

Several research firms recently commented on PFE. Scotiabank boosted their price target on Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a research report on Tuesday. Cantor Fitzgerald increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of "Hold" and an average price target of $28.61.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.